NDA 204308 · Azurity
Epaned Kit
Enalapril Maleate · Oral
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Jul 28, 2017 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2013
Aug 13, 2013
Approved uses
3
Original approval plus efficacy supplements
Registered trials
156
43 Phase 3, 13 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Sep 4, 2014 Supplement 3 · Efficacy LabelLetter
- Sep 4, 2014 Supplement 2 · Efficacy LetterLabel
- Aug 13, 2013 Original approval · Type 3 - New Dosage Form OrphanLabelLetterReview
1 products under this application
- EPANED KIT · ENALAPRIL MALEATE 1MG/ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** · FOR SOLUTION, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Enalapril" as an intervention, any sponsor and status, largest first.
- Prognostic Value of the Circadian Pattern of Ambulatory Blood Pressure for Multiple Risk AssessmentPivotal-lookingCompleted
University of VigoAcademic, hospital or other
NCT00741585 · 21,983 participants · Start Sep 1, 2008 · Primary completion Jun 30, 2018
Drug: Any antihypertensive medication alone or in combination; Any antihypertensive medication alone or in combination · For: Essential Hypertension; Cardiovascular Disease; Stroke and 1 more
Sites: Friol, Spain; A Estrada, Spain; Baiona, Spain · 20 sites in all
- China Stroke Primary Prevention TrialPivotal-lookingCompleted
Shenzhen Ausa Pharmed Co.,LtdIndustry
NCT00794885 · 20,702 participants · Start May 2008 · Primary completion Aug 2013
Drug: Enalapril/folic acid; Enalapril maleate · For: Primary Hypertension
Sites: Anqing, China; Lianyungang, China
- Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired PneumoniaPivotal-lookingRecruiting
UMC UtrechtAcademic, hospital or other
NCT02735707 · 20,000 participants (planned) · Start Apr 11, 2016 · Primary completion Jun 2028
Drug: Ceftriaxone + Macrolide; Moxifloxacin or Levofloxacin and 47 more · For: Respiratory Tract Diseases; Influenza (Pandemic); Influenza and 7 more
Sites: Jacksonville, Florida; Augusta, Georgia; Chicago, Illinois · 408 sites in all
- Primary Prevention of Cardiovascular Disease (CVD) in Pre-diabetic & Pre-hypertensive SubjectsPivotal-lookingStatus unknown
Ramathibodi HospitalAcademic, hospital or other
NCT01364675 · 8,900 participants (planned) · Start Jan 2012 · Primary completion Jul 2016
Drug: Metformin+Enalapril+Simvastatin; Placebo tablet · For: Pre-diabetes; Pre-hypertension
Sites: Muang District, Thailand
- This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart FailurePivotal-lookingTerminated
Novartis PharmaceuticalsNovartis (NVS)
NCT01035255 · 8,442 participants · Start Dec 2009 · Primary completion May 2014
Drug: LCZ696 200 mg BID; Enalapril 10 mg BID · For: Heart Failure With Reduced Ejection Fraction
Sites: Birmingham, Alabama; Huntsville, Alabama; Mobile, Alabama · 1,031 sites in all
- Prevention of Cardiovascular Disease in Middle-aged and Elderly Iranians Using a Single PolyPillPivotal-lookingCompleted
Tehran University of Medical SciencesAcademic, hospital or other
NCT01271985 · 8,410 participants · Start Feb 2011 · Primary completion Jan 2019
Drug: PolyPill · For: Cardiovascular Diseases
Sites: Gonbad, Iran
- Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart FailurePivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT00853658 · 7,064 participants · Start Mar 2009 · Primary completion Oct 2015
Drug: Enalapril; Aliskiren · For: Chronic Heart Failure
Sites: Huntsville, Alabama; Mobile, Alabama; Tucson, Arizona · 806 sites in all
- Systolic Hypertension in Europe Placebo-Controlled TrialPivotal-lookingTerminated
KU LeuvenAcademic, hospital or other
NCT02088450 · 4,695 participants · Start Feb 1990 · Primary completion Feb 1997
Drug: Active treatment with nitrendipine (10-40 mg/day). · For: Isolated Systolic Hypertension
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Angiotensin-neprilysin inhibition versus enalapril in heart failure.
McMurray JJ, Packer M, Desai AS, et al. · N Engl J Med 2014 · Comparative Study, Multicenter Study
- Angiotensin-Neprilysin Inhibition in Acute Decompensated Heart Failure.
Velazquez EJ, Morrow DA, DeVore AD, et al. · N Engl J Med 2019 · Multicenter Study, Randomized Controlled Trial
- Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS).
· N Engl J Med 1987 · Clinical Trial, Randomized Controlled Trial
- The Correlation between Two Angiotensin-Converting Enzyme Inhibitor's Concentrations and Cognition.
Nagy A, Májer R, Csikai E, et al. · Int J Environ Res Public Health 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Cost-effectiveness of folic acid therapy for primary prevention of stroke in patients with hypertension.
Zhang T, Liang Z, Lin T, et al. · BMC Med 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Role of sacubitril-valsartan in the prevention of atrial fibrillation occurrence in patients with heart failure: A systematic review and meta-analysis of randomized controlled trials.
Liu X, Liu H, Wang L, et al. · PLoS One 2022 · Meta-Analysis, Systematic Review
Sponsor: Azurity
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.